(NewsNation) — In a significant step toward potentially extending the lifespan of large- and giant-breed dogs, a San Francisco-based company, Loyal, received conditional approval from the Food and Drug Administration (FDA) for its drug called LOY-001.

The drug, designed to address the shorter lifespans of larger breeds, is anticipated to hit the market as early as 2026, pending FDA approval of Loyal's manufacturing and safety data.

“Loyal was founded with the ambitious goal of developing the first drugs........

© The Hill